+关注
烟雨青山
暂无个人介绍
IP属地：北京
4
关注
0
粉丝
0
主题
0
勋章
主贴
热门
烟雨青山
2021-06-22
伟大的技术
If You Thought These 2 Big Nasdaq Winners Were Done, Think Again<blockquote>如果您认为这两位纳斯达克大赢家已经结束，请再想一想</blockquote>
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3580386497259890","uuid":"3580386497259890","gmtCreate":1617292472953,"gmtModify":1617294490814,"name":"烟雨青山","pinyin":"yyqsyanyuqingshan","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/f75f48d705139e2b67af717077da73c5","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":4,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.05.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"北京","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":129949165,"gmtCreate":1624354047957,"gmtModify":1624354593497,"author":{"id":"3580386497259890","authorId":"3580386497259890","name":"烟雨青山","avatar":"https://static.tigerbbs.com/f75f48d705139e2b67af717077da73c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580386497259890","idStr":"3580386497259890"},"themes":[],"htmlText":"伟大的技术","listText":"伟大的技术","text":"伟大的技术","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129949165","repostId":"1186855284","repostType":2,"repost":{"id":"1186855284","kind":"news","pubTimestamp":1624345153,"share":"https://www.laohu8.com/m/news/1186855284?lang=zh_CN&edition=full","pubTime":"2021-06-22 14:59","market":"us","language":"en","title":"If You Thought These 2 Big Nasdaq Winners Were Done, Think Again<blockquote>如果您认为这两位纳斯达克大赢家已经结束，请再想一想</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186855284","media":"Motley Fool","summary":"On a strong day for the Nasdaq, two highfliers stood out.\n\nVolatility has returned to the stock mark","content":"<p> On a strong day for the Nasdaq, two highfliers stood out. Volatility has returned to the stock market, but finally, the<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)is starting to make waves once again. The tech-heavy index is making a run toward all-time highs, trading within 1% of its high-water mark on Monday afternoon. As of just before 2 p.m. EDT today,the Nasdaq was higher by three-quarters of a percent.</p><p><blockquote>在纳斯达克表现强劲的一天，两名雄心勃勃的人脱颖而出。股市再次出现波动，但最终，<b>纳斯达克复合材料</b>（纳斯达克指数：^IXIC）再次开始掀起波澜。以科技股为主的指数正在逼近历史高点，距离周一下午的高水位不到1%。截至美国东部时间今天下午2点前，纳斯达克上涨了四分之三。</blockquote></p><p> It wasn't that long ago that investors figured that stocks of COVID-19 vaccine manufacturers had already seen their best days. Companies like<b>Moderna</b>(NASDAQ:MRNA)and<b>BioNTech</b>(NASDAQ:BNTX)had seen their share prices start to give up ground as many believed that a vaccinated world would eventually cause revenue and profits to dry up for the vaccine makers. Now, though, it's becoming increasingly clear that the two companies could well have a much brighter future than many had thought.</p><p><blockquote>不久前，投资者还认为COVID-19疫苗制造商的股票已经迎来了最好的日子。公司喜欢<b>现代</b>（纳斯达克：MRNA）和<b>BioNTech</b>（纳斯达克：BNTX）的股价开始下跌，因为许多人认为接种疫苗的世界最终会导致疫苗制造商的收入和利润枯竭。然而现在，越来越清楚的是，这两家公司的未来很可能比许多人想象的要光明得多。</blockquote></p><p> <b>More moves for Moderna and BioNTech</b></p><p><blockquote><b>Moderna和BioNTech的更多举措</b></blockquote></p><p> Shares of the vaccine manufacturers were among the leaders on the Nasdaq today. Moderna's gains amounted to more than 5%, while BioNTech boasted gains of 6% or more on the day.</p><p><blockquote>这些疫苗制造商的股票今天在纳斯达克上名列前茅。Moderna的涨幅超过5%，而BioNTech当天的涨幅为6%或更多。</blockquote></p><p> The general sentiment toward BioNTech and Moderna has been positive because ofjust how effective their vaccines have been. Last month, the U.S. Centers for Disease Control and Prevention released the latest figures on efficacy for the messenger-RNA-based vaccines from the two companies. Data from real-life use showed a reduction in infection risks of 91%. Those who got infected had a 60% lower risk of showing symptoms, and they spent on average six days fewer being sick and two days fewer stuck in bed recovering.</p><p><blockquote>人们对BioNTech和Moderna的普遍看法是积极的，因为他们的疫苗非常有效。上个月，美国疾病控制与预防中心发布了两家公司基于信使RNA的疫苗功效的最新数据。来自实际使用的数据显示，感染风险降低了91%。那些被感染的人出现症状的风险降低了60%，他们生病的时间平均减少了六天，卧床康复的时间也减少了两天。</blockquote></p><p> In addition, the companies have benefited from sustained demand for COVID vaccines from countries around the world. On Monday,BioNTech said that it had received provision approvalof its vaccine from regulators in New Zealand. Over the weekend, the government of the Philippines announced a 40-million-dose agreement with BioNTech and<b>Pfizer</b>(NYSE:PFE)for more vaccine doses as well.</p><p><blockquote>此外，这些公司还受益于世界各国对新冠疫苗的持续需求。周一，BioNTech表示，其疫苗已获得新西兰监管机构的供应批准。上周末，菲律宾政府宣布与BioNTech和<b>辉瑞</b>（纽约证券交易所股票代码：PFE）也需要更多的疫苗剂量。</blockquote></p><p> More broadly, some health officials have started talking about the potential need for vaccine booster shots. It's uncertain at this point whether and how quickly antibody levels from initial vaccinations decline, and so it's entirely possible that even those who've already received vaccinations could need additional doses in the future. From a business standpoint, that would create even further demand for Moderna and BioNTech that could dramatically lengthen the expected flow of revenue stemming from COVID vaccines.</p><p><blockquote>更广泛地说，一些卫生官员已经开始谈论疫苗加强注射的潜在需求。目前还不确定初始疫苗接种后的抗体水平是否会下降以及下降的速度有多快，因此即使是那些已经接种疫苗的人也完全有可能在未来需要额外的剂量。从商业角度来看，这将为Moderna和BioNTech创造进一步的需求，从而大大延长新冠疫苗的预期收入流。</blockquote></p><p> <b>Will existing vaccines be enough?</b></p><p><blockquote><b>现有的疫苗足够吗？</b></blockquote></p><p> The biggest threat on the COVID front comes from the potential for the virus to mutate into more-dangerous variants. Already, theDelta varianthas proved to be more easily transmitted among infected patients and with more-severe health impacts. Future variants could prove even more problematic, and there's no guarantee that existing vaccines will provide protection against them all.</p><p><blockquote>COVID方面最大的威胁来自病毒变异成更危险变种的可能性。Delta变体已经被证明更容易在受感染的患者中传播，并对健康产生更严重的影响。未来的变种可能会带来更大的问题，而且不能保证现有的疫苗能够提供针对所有这些变种的保护。</blockquote></p><p> For the most part, both Moderna's and BioNTech's stock prices seem to reflect little expectation of success beyond the current COVID vaccine products. Yet if anything, COVID has proved that the broader-based investing thesis behind mRNA-based treatment development is sound. Both companies have plans for vaccines and other treatments for a wider variety of different medical conditions, and success anywhere on that front could provide the positive surprise investors need to gain confidence in the long-term futures of these stocks.</p><p><blockquote>在很大程度上，Moderna和BioNTech的股价似乎都反映出除了当前的新冠疫苗产品之外，人们对成功的期望很小。然而，如果说有什么不同的话，那就是COVID已经证明了基于mRNA的治疗开发背后更广泛的投资论点是合理的。两家公司都制定了针对各种不同医疗状况的疫苗和其他治疗方法的计划，这方面的任何成功都可能给投资者带来积极的惊喜，让他们对这些股票的长期未来充满信心。</blockquote></p><p> If you made the mistake of thinking that COVID vaccine stocks would be done once much of the U.S. population had been vaccinated, you aren't alone. But you might be surprised at how much staying power BioNTech and Moderna could have -- especially if a few things end up working out in their favor.</p><p><blockquote>如果你错误地认为一旦美国大部分人口接种了疫苗，COVID疫苗库存就会耗尽，那么你并不孤单。但你可能会对BioNTech和Moderna的持久力感到惊讶——特别是如果一些事情最终对他们有利的话。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>If You Thought These 2 Big Nasdaq Winners Were Done, Think Again<blockquote>如果您认为这两位纳斯达克大赢家已经结束，请再想一想</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIf You Thought These 2 Big Nasdaq Winners Were Done, Think Again<blockquote>如果您认为这两位纳斯达克大赢家已经结束，请再想一想</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-06-22 14:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p> On a strong day for the Nasdaq, two highfliers stood out. Volatility has returned to the stock market, but finally, the<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)is starting to make waves once again. The tech-heavy index is making a run toward all-time highs, trading within 1% of its high-water mark on Monday afternoon. As of just before 2 p.m. EDT today,the Nasdaq was higher by three-quarters of a percent.</p><p><blockquote>在纳斯达克表现强劲的一天，两名雄心勃勃的人脱颖而出。股市再次出现波动，但最终，<b>纳斯达克复合材料</b>（纳斯达克指数：^IXIC）再次开始掀起波澜。以科技股为主的指数正在逼近历史高点，距离周一下午的高水位不到1%。截至美国东部时间今天下午2点前，纳斯达克上涨了四分之三。</blockquote></p><p> It wasn't that long ago that investors figured that stocks of COVID-19 vaccine manufacturers had already seen their best days. Companies like<b>Moderna</b>(NASDAQ:MRNA)and<b>BioNTech</b>(NASDAQ:BNTX)had seen their share prices start to give up ground as many believed that a vaccinated world would eventually cause revenue and profits to dry up for the vaccine makers. Now, though, it's becoming increasingly clear that the two companies could well have a much brighter future than many had thought.</p><p><blockquote>不久前，投资者还认为COVID-19疫苗制造商的股票已经迎来了最好的日子。公司喜欢<b>现代</b>（纳斯达克：MRNA）和<b>BioNTech</b>（纳斯达克：BNTX）的股价开始下跌，因为许多人认为接种疫苗的世界最终会导致疫苗制造商的收入和利润枯竭。然而现在，越来越清楚的是，这两家公司的未来很可能比许多人想象的要光明得多。</blockquote></p><p> <b>More moves for Moderna and BioNTech</b></p><p><blockquote><b>Moderna和BioNTech的更多举措</b></blockquote></p><p> Shares of the vaccine manufacturers were among the leaders on the Nasdaq today. Moderna's gains amounted to more than 5%, while BioNTech boasted gains of 6% or more on the day.</p><p><blockquote>这些疫苗制造商的股票今天在纳斯达克上名列前茅。Moderna的涨幅超过5%，而BioNTech当天的涨幅为6%或更多。</blockquote></p><p> The general sentiment toward BioNTech and Moderna has been positive because ofjust how effective their vaccines have been. Last month, the U.S. Centers for Disease Control and Prevention released the latest figures on efficacy for the messenger-RNA-based vaccines from the two companies. Data from real-life use showed a reduction in infection risks of 91%. Those who got infected had a 60% lower risk of showing symptoms, and they spent on average six days fewer being sick and two days fewer stuck in bed recovering.</p><p><blockquote>人们对BioNTech和Moderna的普遍看法是积极的，因为他们的疫苗非常有效。上个月，美国疾病控制与预防中心发布了两家公司基于信使RNA的疫苗功效的最新数据。来自实际使用的数据显示，感染风险降低了91%。那些被感染的人出现症状的风险降低了60%，他们生病的时间平均减少了六天，卧床康复的时间也减少了两天。</blockquote></p><p> In addition, the companies have benefited from sustained demand for COVID vaccines from countries around the world. On Monday,BioNTech said that it had received provision approvalof its vaccine from regulators in New Zealand. Over the weekend, the government of the Philippines announced a 40-million-dose agreement with BioNTech and<b>Pfizer</b>(NYSE:PFE)for more vaccine doses as well.</p><p><blockquote>此外，这些公司还受益于世界各国对新冠疫苗的持续需求。周一，BioNTech表示，其疫苗已获得新西兰监管机构的供应批准。上周末，菲律宾政府宣布与BioNTech和<b>辉瑞</b>（纽约证券交易所股票代码：PFE）也需要更多的疫苗剂量。</blockquote></p><p> More broadly, some health officials have started talking about the potential need for vaccine booster shots. It's uncertain at this point whether and how quickly antibody levels from initial vaccinations decline, and so it's entirely possible that even those who've already received vaccinations could need additional doses in the future. From a business standpoint, that would create even further demand for Moderna and BioNTech that could dramatically lengthen the expected flow of revenue stemming from COVID vaccines.</p><p><blockquote>更广泛地说，一些卫生官员已经开始谈论疫苗加强注射的潜在需求。目前还不确定初始疫苗接种后的抗体水平是否会下降以及下降的速度有多快，因此即使是那些已经接种疫苗的人也完全有可能在未来需要额外的剂量。从商业角度来看，这将为Moderna和BioNTech创造进一步的需求，从而大大延长新冠疫苗的预期收入流。</blockquote></p><p> <b>Will existing vaccines be enough?</b></p><p><blockquote><b>现有的疫苗足够吗？</b></blockquote></p><p> The biggest threat on the COVID front comes from the potential for the virus to mutate into more-dangerous variants. Already, theDelta varianthas proved to be more easily transmitted among infected patients and with more-severe health impacts. Future variants could prove even more problematic, and there's no guarantee that existing vaccines will provide protection against them all.</p><p><blockquote>COVID方面最大的威胁来自病毒变异成更危险变种的可能性。Delta变体已经被证明更容易在受感染的患者中传播，并对健康产生更严重的影响。未来的变种可能会带来更大的问题，而且不能保证现有的疫苗能够提供针对所有这些变种的保护。</blockquote></p><p> For the most part, both Moderna's and BioNTech's stock prices seem to reflect little expectation of success beyond the current COVID vaccine products. Yet if anything, COVID has proved that the broader-based investing thesis behind mRNA-based treatment development is sound. Both companies have plans for vaccines and other treatments for a wider variety of different medical conditions, and success anywhere on that front could provide the positive surprise investors need to gain confidence in the long-term futures of these stocks.</p><p><blockquote>在很大程度上，Moderna和BioNTech的股价似乎都反映出除了当前的新冠疫苗产品之外，人们对成功的期望很小。然而，如果说有什么不同的话，那就是COVID已经证明了基于mRNA的治疗开发背后更广泛的投资论点是合理的。两家公司都制定了针对各种不同医疗状况的疫苗和其他治疗方法的计划，这方面的任何成功都可能给投资者带来积极的惊喜，让他们对这些股票的长期未来充满信心。</blockquote></p><p> If you made the mistake of thinking that COVID vaccine stocks would be done once much of the U.S. population had been vaccinated, you aren't alone. But you might be surprised at how much staying power BioNTech and Moderna could have -- especially if a few things end up working out in their favor.</p><p><blockquote>如果你错误地认为一旦美国大部分人口接种了疫苗，COVID疫苗库存就会耗尽，那么你并不孤单。但你可能会对BioNTech和Moderna的持久力感到惊讶——特别是如果一些事情最终对他们有利的话。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/06/21/if-you-thought-big-nasdaq-winners-done-think-again/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/06/21/if-you-thought-big-nasdaq-winners-done-think-again/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186855284","content_text":"On a strong day for the Nasdaq, two highfliers stood out.\n\nVolatility has returned to the stock market, but finally, theNasdaq Composite(NASDAQINDEX:^IXIC)is starting to make waves once again. The tech-heavy index is making a run toward all-time highs, trading within 1% of its high-water mark on Monday afternoon. As of just before 2 p.m. EDT today,the Nasdaq was higher by three-quarters of a percent.\nIt wasn't that long ago that investors figured that stocks of COVID-19 vaccine manufacturers had already seen their best days. Companies likeModerna(NASDAQ:MRNA)andBioNTech(NASDAQ:BNTX)had seen their share prices start to give up ground as many believed that a vaccinated world would eventually cause revenue and profits to dry up for the vaccine makers. Now, though, it's becoming increasingly clear that the two companies could well have a much brighter future than many had thought.\nMore moves for Moderna and BioNTech\nShares of the vaccine manufacturers were among the leaders on the Nasdaq today. Moderna's gains amounted to more than 5%, while BioNTech boasted gains of 6% or more on the day.\nThe general sentiment toward BioNTech and Moderna has been positive because ofjust how effective their vaccines have been. Last month, the U.S. Centers for Disease Control and Prevention released the latest figures on efficacy for the messenger-RNA-based vaccines from the two companies. Data from real-life use showed a reduction in infection risks of 91%. Those who got infected had a 60% lower risk of showing symptoms, and they spent on average six days fewer being sick and two days fewer stuck in bed recovering.\nIn addition, the companies have benefited from sustained demand for COVID vaccines from countries around the world. On Monday,BioNTech said that it had received provision approvalof its vaccine from regulators in New Zealand. Over the weekend, the government of the Philippines announced a 40-million-dose agreement with BioNTech andPfizer(NYSE:PFE)for more vaccine doses as well.\nMore broadly, some health officials have started talking about the potential need for vaccine booster shots. It's uncertain at this point whether and how quickly antibody levels from initial vaccinations decline, and so it's entirely possible that even those who've already received vaccinations could need additional doses in the future. From a business standpoint, that would create even further demand for Moderna and BioNTech that could dramatically lengthen the expected flow of revenue stemming from COVID vaccines.\nWill existing vaccines be enough?\nThe biggest threat on the COVID front comes from the potential for the virus to mutate into more-dangerous variants. Already, theDelta varianthas proved to be more easily transmitted among infected patients and with more-severe health impacts. Future variants could prove even more problematic, and there's no guarantee that existing vaccines will provide protection against them all.\nFor the most part, both Moderna's and BioNTech's stock prices seem to reflect little expectation of success beyond the current COVID vaccine products. Yet if anything, COVID has proved that the broader-based investing thesis behind mRNA-based treatment development is sound. Both companies have plans for vaccines and other treatments for a wider variety of different medical conditions, and success anywhere on that front could provide the positive surprise investors need to gain confidence in the long-term futures of these stocks.\nIf you made the mistake of thinking that COVID vaccine stocks would be done once much of the U.S. population had been vaccinated, you aren't alone. But you might be surprised at how much staying power BioNTech and Moderna could have -- especially if a few things end up working out in their favor.","news_type":1,"symbols_score_info":{"BNTX":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1342,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":129949165,"gmtCreate":1624354047957,"gmtModify":1624354593497,"author":{"id":"3580386497259890","authorId":"3580386497259890","name":"烟雨青山","avatar":"https://static.tigerbbs.com/f75f48d705139e2b67af717077da73c5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580386497259890","idStr":"3580386497259890"},"themes":[],"htmlText":"伟大的技术","listText":"伟大的技术","text":"伟大的技术","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129949165","repostId":"1186855284","repostType":2,"repost":{"id":"1186855284","kind":"news","pubTimestamp":1624345153,"share":"https://www.laohu8.com/m/news/1186855284?lang=zh_CN&edition=full","pubTime":"2021-06-22 14:59","market":"us","language":"en","title":"If You Thought These 2 Big Nasdaq Winners Were Done, Think Again<blockquote>如果您认为这两位纳斯达克大赢家已经结束，请再想一想</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186855284","media":"Motley Fool","summary":"On a strong day for the Nasdaq, two highfliers stood out.\n\nVolatility has returned to the stock mark","content":"<p> On a strong day for the Nasdaq, two highfliers stood out. Volatility has returned to the stock market, but finally, the<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)is starting to make waves once again. The tech-heavy index is making a run toward all-time highs, trading within 1% of its high-water mark on Monday afternoon. As of just before 2 p.m. EDT today,the Nasdaq was higher by three-quarters of a percent.</p><p><blockquote>在纳斯达克表现强劲的一天，两名雄心勃勃的人脱颖而出。股市再次出现波动，但最终，<b>纳斯达克复合材料</b>（纳斯达克指数：^IXIC）再次开始掀起波澜。以科技股为主的指数正在逼近历史高点，距离周一下午的高水位不到1%。截至美国东部时间今天下午2点前，纳斯达克上涨了四分之三。</blockquote></p><p> It wasn't that long ago that investors figured that stocks of COVID-19 vaccine manufacturers had already seen their best days. Companies like<b>Moderna</b>(NASDAQ:MRNA)and<b>BioNTech</b>(NASDAQ:BNTX)had seen their share prices start to give up ground as many believed that a vaccinated world would eventually cause revenue and profits to dry up for the vaccine makers. Now, though, it's becoming increasingly clear that the two companies could well have a much brighter future than many had thought.</p><p><blockquote>不久前，投资者还认为COVID-19疫苗制造商的股票已经迎来了最好的日子。公司喜欢<b>现代</b>（纳斯达克：MRNA）和<b>BioNTech</b>（纳斯达克：BNTX）的股价开始下跌，因为许多人认为接种疫苗的世界最终会导致疫苗制造商的收入和利润枯竭。然而现在，越来越清楚的是，这两家公司的未来很可能比许多人想象的要光明得多。</blockquote></p><p> <b>More moves for Moderna and BioNTech</b></p><p><blockquote><b>Moderna和BioNTech的更多举措</b></blockquote></p><p> Shares of the vaccine manufacturers were among the leaders on the Nasdaq today. Moderna's gains amounted to more than 5%, while BioNTech boasted gains of 6% or more on the day.</p><p><blockquote>这些疫苗制造商的股票今天在纳斯达克上名列前茅。Moderna的涨幅超过5%，而BioNTech当天的涨幅为6%或更多。</blockquote></p><p> The general sentiment toward BioNTech and Moderna has been positive because ofjust how effective their vaccines have been. Last month, the U.S. Centers for Disease Control and Prevention released the latest figures on efficacy for the messenger-RNA-based vaccines from the two companies. Data from real-life use showed a reduction in infection risks of 91%. Those who got infected had a 60% lower risk of showing symptoms, and they spent on average six days fewer being sick and two days fewer stuck in bed recovering.</p><p><blockquote>人们对BioNTech和Moderna的普遍看法是积极的，因为他们的疫苗非常有效。上个月，美国疾病控制与预防中心发布了两家公司基于信使RNA的疫苗功效的最新数据。来自实际使用的数据显示，感染风险降低了91%。那些被感染的人出现症状的风险降低了60%，他们生病的时间平均减少了六天，卧床康复的时间也减少了两天。</blockquote></p><p> In addition, the companies have benefited from sustained demand for COVID vaccines from countries around the world. On Monday,BioNTech said that it had received provision approvalof its vaccine from regulators in New Zealand. Over the weekend, the government of the Philippines announced a 40-million-dose agreement with BioNTech and<b>Pfizer</b>(NYSE:PFE)for more vaccine doses as well.</p><p><blockquote>此外，这些公司还受益于世界各国对新冠疫苗的持续需求。周一，BioNTech表示，其疫苗已获得新西兰监管机构的供应批准。上周末，菲律宾政府宣布与BioNTech和<b>辉瑞</b>（纽约证券交易所股票代码：PFE）也需要更多的疫苗剂量。</blockquote></p><p> More broadly, some health officials have started talking about the potential need for vaccine booster shots. It's uncertain at this point whether and how quickly antibody levels from initial vaccinations decline, and so it's entirely possible that even those who've already received vaccinations could need additional doses in the future. From a business standpoint, that would create even further demand for Moderna and BioNTech that could dramatically lengthen the expected flow of revenue stemming from COVID vaccines.</p><p><blockquote>更广泛地说，一些卫生官员已经开始谈论疫苗加强注射的潜在需求。目前还不确定初始疫苗接种后的抗体水平是否会下降以及下降的速度有多快，因此即使是那些已经接种疫苗的人也完全有可能在未来需要额外的剂量。从商业角度来看，这将为Moderna和BioNTech创造进一步的需求，从而大大延长新冠疫苗的预期收入流。</blockquote></p><p> <b>Will existing vaccines be enough?</b></p><p><blockquote><b>现有的疫苗足够吗？</b></blockquote></p><p> The biggest threat on the COVID front comes from the potential for the virus to mutate into more-dangerous variants. Already, theDelta varianthas proved to be more easily transmitted among infected patients and with more-severe health impacts. Future variants could prove even more problematic, and there's no guarantee that existing vaccines will provide protection against them all.</p><p><blockquote>COVID方面最大的威胁来自病毒变异成更危险变种的可能性。Delta变体已经被证明更容易在受感染的患者中传播，并对健康产生更严重的影响。未来的变种可能会带来更大的问题，而且不能保证现有的疫苗能够提供针对所有这些变种的保护。</blockquote></p><p> For the most part, both Moderna's and BioNTech's stock prices seem to reflect little expectation of success beyond the current COVID vaccine products. Yet if anything, COVID has proved that the broader-based investing thesis behind mRNA-based treatment development is sound. Both companies have plans for vaccines and other treatments for a wider variety of different medical conditions, and success anywhere on that front could provide the positive surprise investors need to gain confidence in the long-term futures of these stocks.</p><p><blockquote>在很大程度上，Moderna和BioNTech的股价似乎都反映出除了当前的新冠疫苗产品之外，人们对成功的期望很小。然而，如果说有什么不同的话，那就是COVID已经证明了基于mRNA的治疗开发背后更广泛的投资论点是合理的。两家公司都制定了针对各种不同医疗状况的疫苗和其他治疗方法的计划，这方面的任何成功都可能给投资者带来积极的惊喜，让他们对这些股票的长期未来充满信心。</blockquote></p><p> If you made the mistake of thinking that COVID vaccine stocks would be done once much of the U.S. population had been vaccinated, you aren't alone. But you might be surprised at how much staying power BioNTech and Moderna could have -- especially if a few things end up working out in their favor.</p><p><blockquote>如果你错误地认为一旦美国大部分人口接种了疫苗，COVID疫苗库存就会耗尽，那么你并不孤单。但你可能会对BioNTech和Moderna的持久力感到惊讶——特别是如果一些事情最终对他们有利的话。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>If You Thought These 2 Big Nasdaq Winners Were Done, Think Again<blockquote>如果您认为这两位纳斯达克大赢家已经结束，请再想一想</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIf You Thought These 2 Big Nasdaq Winners Were Done, Think Again<blockquote>如果您认为这两位纳斯达克大赢家已经结束，请再想一想</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-06-22 14:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p> On a strong day for the Nasdaq, two highfliers stood out. Volatility has returned to the stock market, but finally, the<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)is starting to make waves once again. The tech-heavy index is making a run toward all-time highs, trading within 1% of its high-water mark on Monday afternoon. As of just before 2 p.m. EDT today,the Nasdaq was higher by three-quarters of a percent.</p><p><blockquote>在纳斯达克表现强劲的一天，两名雄心勃勃的人脱颖而出。股市再次出现波动，但最终，<b>纳斯达克复合材料</b>（纳斯达克指数：^IXIC）再次开始掀起波澜。以科技股为主的指数正在逼近历史高点，距离周一下午的高水位不到1%。截至美国东部时间今天下午2点前，纳斯达克上涨了四分之三。</blockquote></p><p> It wasn't that long ago that investors figured that stocks of COVID-19 vaccine manufacturers had already seen their best days. Companies like<b>Moderna</b>(NASDAQ:MRNA)and<b>BioNTech</b>(NASDAQ:BNTX)had seen their share prices start to give up ground as many believed that a vaccinated world would eventually cause revenue and profits to dry up for the vaccine makers. Now, though, it's becoming increasingly clear that the two companies could well have a much brighter future than many had thought.</p><p><blockquote>不久前，投资者还认为COVID-19疫苗制造商的股票已经迎来了最好的日子。公司喜欢<b>现代</b>（纳斯达克：MRNA）和<b>BioNTech</b>（纳斯达克：BNTX）的股价开始下跌，因为许多人认为接种疫苗的世界最终会导致疫苗制造商的收入和利润枯竭。然而现在，越来越清楚的是，这两家公司的未来很可能比许多人想象的要光明得多。</blockquote></p><p> <b>More moves for Moderna and BioNTech</b></p><p><blockquote><b>Moderna和BioNTech的更多举措</b></blockquote></p><p> Shares of the vaccine manufacturers were among the leaders on the Nasdaq today. Moderna's gains amounted to more than 5%, while BioNTech boasted gains of 6% or more on the day.</p><p><blockquote>这些疫苗制造商的股票今天在纳斯达克上名列前茅。Moderna的涨幅超过5%，而BioNTech当天的涨幅为6%或更多。</blockquote></p><p> The general sentiment toward BioNTech and Moderna has been positive because ofjust how effective their vaccines have been. Last month, the U.S. Centers for Disease Control and Prevention released the latest figures on efficacy for the messenger-RNA-based vaccines from the two companies. Data from real-life use showed a reduction in infection risks of 91%. Those who got infected had a 60% lower risk of showing symptoms, and they spent on average six days fewer being sick and two days fewer stuck in bed recovering.</p><p><blockquote>人们对BioNTech和Moderna的普遍看法是积极的，因为他们的疫苗非常有效。上个月，美国疾病控制与预防中心发布了两家公司基于信使RNA的疫苗功效的最新数据。来自实际使用的数据显示，感染风险降低了91%。那些被感染的人出现症状的风险降低了60%，他们生病的时间平均减少了六天，卧床康复的时间也减少了两天。</blockquote></p><p> In addition, the companies have benefited from sustained demand for COVID vaccines from countries around the world. On Monday,BioNTech said that it had received provision approvalof its vaccine from regulators in New Zealand. Over the weekend, the government of the Philippines announced a 40-million-dose agreement with BioNTech and<b>Pfizer</b>(NYSE:PFE)for more vaccine doses as well.</p><p><blockquote>此外，这些公司还受益于世界各国对新冠疫苗的持续需求。周一，BioNTech表示，其疫苗已获得新西兰监管机构的供应批准。上周末，菲律宾政府宣布与BioNTech和<b>辉瑞</b>（纽约证券交易所股票代码：PFE）也需要更多的疫苗剂量。</blockquote></p><p> More broadly, some health officials have started talking about the potential need for vaccine booster shots. It's uncertain at this point whether and how quickly antibody levels from initial vaccinations decline, and so it's entirely possible that even those who've already received vaccinations could need additional doses in the future. From a business standpoint, that would create even further demand for Moderna and BioNTech that could dramatically lengthen the expected flow of revenue stemming from COVID vaccines.</p><p><blockquote>更广泛地说，一些卫生官员已经开始谈论疫苗加强注射的潜在需求。目前还不确定初始疫苗接种后的抗体水平是否会下降以及下降的速度有多快，因此即使是那些已经接种疫苗的人也完全有可能在未来需要额外的剂量。从商业角度来看，这将为Moderna和BioNTech创造进一步的需求，从而大大延长新冠疫苗的预期收入流。</blockquote></p><p> <b>Will existing vaccines be enough?</b></p><p><blockquote><b>现有的疫苗足够吗？</b></blockquote></p><p> The biggest threat on the COVID front comes from the potential for the virus to mutate into more-dangerous variants. Already, theDelta varianthas proved to be more easily transmitted among infected patients and with more-severe health impacts. Future variants could prove even more problematic, and there's no guarantee that existing vaccines will provide protection against them all.</p><p><blockquote>COVID方面最大的威胁来自病毒变异成更危险变种的可能性。Delta变体已经被证明更容易在受感染的患者中传播，并对健康产生更严重的影响。未来的变种可能会带来更大的问题，而且不能保证现有的疫苗能够提供针对所有这些变种的保护。</blockquote></p><p> For the most part, both Moderna's and BioNTech's stock prices seem to reflect little expectation of success beyond the current COVID vaccine products. Yet if anything, COVID has proved that the broader-based investing thesis behind mRNA-based treatment development is sound. Both companies have plans for vaccines and other treatments for a wider variety of different medical conditions, and success anywhere on that front could provide the positive surprise investors need to gain confidence in the long-term futures of these stocks.</p><p><blockquote>在很大程度上，Moderna和BioNTech的股价似乎都反映出除了当前的新冠疫苗产品之外，人们对成功的期望很小。然而，如果说有什么不同的话，那就是COVID已经证明了基于mRNA的治疗开发背后更广泛的投资论点是合理的。两家公司都制定了针对各种不同医疗状况的疫苗和其他治疗方法的计划，这方面的任何成功都可能给投资者带来积极的惊喜，让他们对这些股票的长期未来充满信心。</blockquote></p><p> If you made the mistake of thinking that COVID vaccine stocks would be done once much of the U.S. population had been vaccinated, you aren't alone. But you might be surprised at how much staying power BioNTech and Moderna could have -- especially if a few things end up working out in their favor.</p><p><blockquote>如果你错误地认为一旦美国大部分人口接种了疫苗，COVID疫苗库存就会耗尽，那么你并不孤单。但你可能会对BioNTech和Moderna的持久力感到惊讶——特别是如果一些事情最终对他们有利的话。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/06/21/if-you-thought-big-nasdaq-winners-done-think-again/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/06/21/if-you-thought-big-nasdaq-winners-done-think-again/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186855284","content_text":"On a strong day for the Nasdaq, two highfliers stood out.\n\nVolatility has returned to the stock market, but finally, theNasdaq Composite(NASDAQINDEX:^IXIC)is starting to make waves once again. The tech-heavy index is making a run toward all-time highs, trading within 1% of its high-water mark on Monday afternoon. As of just before 2 p.m. EDT today,the Nasdaq was higher by three-quarters of a percent.\nIt wasn't that long ago that investors figured that stocks of COVID-19 vaccine manufacturers had already seen their best days. Companies likeModerna(NASDAQ:MRNA)andBioNTech(NASDAQ:BNTX)had seen their share prices start to give up ground as many believed that a vaccinated world would eventually cause revenue and profits to dry up for the vaccine makers. Now, though, it's becoming increasingly clear that the two companies could well have a much brighter future than many had thought.\nMore moves for Moderna and BioNTech\nShares of the vaccine manufacturers were among the leaders on the Nasdaq today. Moderna's gains amounted to more than 5%, while BioNTech boasted gains of 6% or more on the day.\nThe general sentiment toward BioNTech and Moderna has been positive because ofjust how effective their vaccines have been. Last month, the U.S. Centers for Disease Control and Prevention released the latest figures on efficacy for the messenger-RNA-based vaccines from the two companies. Data from real-life use showed a reduction in infection risks of 91%. Those who got infected had a 60% lower risk of showing symptoms, and they spent on average six days fewer being sick and two days fewer stuck in bed recovering.\nIn addition, the companies have benefited from sustained demand for COVID vaccines from countries around the world. On Monday,BioNTech said that it had received provision approvalof its vaccine from regulators in New Zealand. Over the weekend, the government of the Philippines announced a 40-million-dose agreement with BioNTech andPfizer(NYSE:PFE)for more vaccine doses as well.\nMore broadly, some health officials have started talking about the potential need for vaccine booster shots. It's uncertain at this point whether and how quickly antibody levels from initial vaccinations decline, and so it's entirely possible that even those who've already received vaccinations could need additional doses in the future. From a business standpoint, that would create even further demand for Moderna and BioNTech that could dramatically lengthen the expected flow of revenue stemming from COVID vaccines.\nWill existing vaccines be enough?\nThe biggest threat on the COVID front comes from the potential for the virus to mutate into more-dangerous variants. Already, theDelta varianthas proved to be more easily transmitted among infected patients and with more-severe health impacts. Future variants could prove even more problematic, and there's no guarantee that existing vaccines will provide protection against them all.\nFor the most part, both Moderna's and BioNTech's stock prices seem to reflect little expectation of success beyond the current COVID vaccine products. Yet if anything, COVID has proved that the broader-based investing thesis behind mRNA-based treatment development is sound. Both companies have plans for vaccines and other treatments for a wider variety of different medical conditions, and success anywhere on that front could provide the positive surprise investors need to gain confidence in the long-term futures of these stocks.\nIf you made the mistake of thinking that COVID vaccine stocks would be done once much of the U.S. population had been vaccinated, you aren't alone. But you might be surprised at how much staying power BioNTech and Moderna could have -- especially if a few things end up working out in their favor.","news_type":1,"symbols_score_info":{"BNTX":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1342,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
